

Lösningar för högflödesfistlar


Solutions in high-flow fistulas

Nick Inston PhD FRCS



Queen Elizabeth Hospital


Birmingham

UK



normal





All working fistulas
create a high flow
situation

=

Left to right shunt
from the high-
resistance arterial
circulation to the
low-resistance
venous system,

=

hyperdynamic
circulatory state.

Creation of
an AVF

Enlargement of both atria and ventricles, elevated left ventricular end-diastolic volume (LVEDV) and increased wall tension

Drop in systemic vascular resistance



adaptive increase in CO

These structural adaptations can be detected as early as days 3-14 post-AVF creation, with notable increases in left atrial diameter (LAD) and brain natriuretic peptide (BNP) levels



higher stroke volumes (SV),
ejection fraction (EF)
cardiac index (CI)

Atrial natriuretic peptide (ANP) rises in response to atrial stretch due to increased venous return

With prolonged exposure, the heart develop eccentric hypertrophy and impaired diastolic filling.

In severe cases, these changes may evolve into impaired systolic function and overt HOCF, even in patients with an initially preserved EF

What is a high flow fistula?

Definitions and thresholds for high-flow access lack consensus.

Vascular Access Society & KDOQI guidelines

Flow (Qa) between 1–1.5 L/min or a Qa >20% of the cardiac output (CO)

European Society for Vascular Surgery (ESVS) guidelines 2018

recommend close surveillance for any AVFs with a Qa >1.5L/min

Spanish guidelines

Qa >2L/min or Qa >30% of cardiac output

Incidence


Incidence has been reported as low as 4% in general haemodialysis cohorts by Gerrickens

But reported as high as 25.7- 31.4% by other authors

Prevention

Original research articles

Feasibility of a 3 mm arteriotomy for brachiocephalic fistula formation

Jeremy Crane, Safa Salim, and Rowland Storey 

Secondary patency at 6 and 12 months was 94% and 91%, respectively.

Steal in 5.4%

No incidences of high flow fistula

FULL TEXT ARTICLE



Small Arteriovenous Anastomosis in Fistula Creation: Establishing a Functional Vascular Access while Minimizing Steal Syndrome  

Michael A. Turner, Asma Mathlouthi, Rohini J. Patel, Mark Perreault, Mahmoud B. Malas and Omar Al-Nouri
Annals of Vascular Surgery, 2024-02-01, Volume 99, Pages 142-147, Copyright © 2023





	Small	Regular
Anastamosis size	5-6mm	8-10mm
Primary patency	46.9%	67.9%
Functional patency, N (%)	82.2%	87.7%
Steal	0%	9%




3.6mm Punch
Maturation was achieved in 98.2% of cases.

Mean AVF flow at 12 months was 1080 ± 170 mL/min (range: 920–1460 mL/min)

Original research article


Sizing matters not: Technical standardization of small anastomoses in AVF surgery for complex patients

Marco Franchin , Maria Cristina Cervarolo, Alessandra Bandiera, Sara Monteleone, Alberto Inguscio, Gabriele Piffaretti, and Matteo Tozzi

Prevention

“High Flow” access with outflow stenosis



Treat the inflow not balloon the outflow



Treatment - Ligation

100% effective in reducing high flow

Risks = stump aneurysm



Naganuma T. Arteriovenous Fistula Closure Using a Simple Ligation Technique After Kidney Transplantation, *Transplantation Proceedings*, Volume 56, Issue 3, 2024, Pages 526-529, ISSN 0041-1345

Among 60 kidney transplant patients after AVF closure, **8% of patients had symptomatic arterial thrombosis** and 5% had a symptomatic feeding artery aneurysm.

Prospective ultrasound revealed additional asymptomatic **arterial complications** in nine patients (**18% incidence**).

The incidence of **asymptomatic arterial thrombosis was 14%** and some extended up to the axillary artery. The incidence of brachial artery aneurysms was 6%.

Treatment – Flow reduction - Banding

Teixeira et al

227

TABLE I - Characteristics of patients undergoing banding because of hand ischaemia and high flow access

	All patients (n = 119)	HAIDI (n = 64)	HFA (n = 55)	p value
Age (y)	61 (21-90)	65.5 (22-90)	56.4 (21-87)	0.001*
Gender, n (%)				
Male	72 (60.5%)	37 (57.8%)	35 (53.6%)	0.575
Comorbid conditions, n (%)				
Diabetes	49 (41.2%)	36 (56.3%)	13 (23.6%)	0.004*
Hypertension	19 (15.9%)	9 (14.1%)	10 (18.2%)	0.620
Peripheral artery disease	18 (15.1%)	12 (18.8%)	6 (10.9%)	0.307
Medications, n (%)				
Antiaggregation	61 (51.3%)	34 (53.1%)	27 (49.1%)	0.715
Anticoagulation	15 (12.6%)	9 (14.1%)	6 (10.9%)	0.783
Vascular access, n (%)				
Forearm	8 (6.7%)	5 (7.8%)	3 (5.5%)	-
Upper arm		55 (85.9%)	52 (94.5%)	-
Graft	4 (3.4%)	4 (6.3%)	-	-
Fistula flow \pm SD (mL/min)	2073 \pm 820	1689 \pm 721	2435 \pm 744	0.001*

HAIDI = haemodialysis access-induced distal ischaemia; HFA = high flow access.

* Indicates statistically significant difference.



TABLE III - Number of patients with banding-related complications. Technical failure, recurrence of symptoms, requiring new banding. Excessive banding, access with inappropriate access flow caused by banding

Complications	All patients (n = 119)	HAIDI (n = 64)	HFA (n = 55)
Technical failure	20	10	10
Excessive banding	4	4	-
Thrombosis	6	4	2
Rupture	3	-	3
False aneurysm	1	-	1
Total	34 (28.6%)	18 (28.1%)	16 (29.1%)

HAIDI = haemodialysis access-induced distal ischaemia; HFA = high flow access.

95% = upper arm AVFs

20% = technical failure

“Precision” Banding





Fig. 1. The photo shows a precise banding of a HF—AVF using a coronary dilator as a dowel for reliable sizing of the restriction site. This simple flow restriction is created adjacent to the AVF anastomosis using polypropylene suture and sized in 0.5-mm increments. AVF flow rates are remeasured until the target access flow is achieved (500–800 mL/min). A second suture was placed at the same site for security.



N= 12

Resolution of cardiac symptoms in 100%

1 thrombosis

Treatment – Flow reduction - Banding

Teixeira et al

TABLE VI - Study results for banding procedure

First author	Clinical	Number of patients	Free of symptoms (%)
Odland (18)	HAIDI	16	100
DeCaprio (5)	HAIDI	11	91
Morsy (19)	HAIDI	6	100
Aschwanden (20)	HAIDI	3	100
Zanow (21)	HAIDI (n = 78)	95	86 (HAIDI)
	HFA (n = 17)		96 (HFA)
van Hoek (15)	HAIDI (n = 9)	17	88
	HFA (n = 8)		
Gupta (22)	HAIDI	21	52
Jennings (23)	HFA and central stenosis	22	100
Vaes (16)	HFA	50	48
Leake (6)	HAIDI	38	75

AVF = arteriovenous fistula; AVG = arteriovenous graft; HAIDI = haemodialysis access-induced distal ischaemia; HFA = high flow access

Most reports are HAIDI not HFA

Results variable

Jennings 100% success

Zanow 96% success HFA

Vaes 48% success HFA




Fig 1. Access flow (mL/min) is plotted during 12 months of follow-up after banding. The *upper curve* reflects patients developing recurrent high-flow access (HFA; >2000 mL/min). The *lower curve* illustrates patients with access flow that remained <2000 mL/min. * $P < .05$.

Post op flow
predicts recurrence

BUT

Rebound flow
increase occurs
in all

Minimally invasive limited ligated endoluminal assisted revascularisation (MILLER) procedure




Figure 5. Angiography during minimally invasive limited ligated endoluminal-assisted revascularization (MILLER) procedure. (A) An inflated 5 mm angioplasty balloon (black arrow) is guided to the proximal arteriovenous graft (AVG) site. A hemostat is used to designate the area for skin incisions. (B) Post-procedure imaging demonstrates a waist in the AVG (black arrow) and distal flow in the brachial artery (red arrow).

Table 1. Comparison of available MILLER procedure series

Group	Presentation	No. Patients	Clinical Success		Band Patency	Primary Access Patency	Secondary Access Patency	Follow Up (Months)
			One Banding	Multiple Bandings				
Goel et al. [5]	Steal	16	N/A	N/A	100% ¹	100% ¹	77%	3, 36
Miller et al. [7]	HF	69	94%	100%	85% ²	63% ¹	89% ⁴	11
	Steal	114	89%	96%	75% ²	52% ¹	90% ⁴	
Shukla et al. [26]	Steal	20	75%	95%	77% ²	95% ^{1,*}	86% ^{1,‡}	18
Shintaku et al. [27]	HF	7	N/A	N/A	N/A	N/A	83% ³	46
	Steal	5	0%	0%	N/A	N/A	25% ³	

HF = High-Flow; N/A = not available; ¹ 3 months; ² 6 months; ³ 12 months; ⁴ 24 months. * Post intervention assisted primary patency. ‡ Low follow-up limited long term secondary patency data.

High patency
Success 94-100% in HF

Flow reduction – external Wrap

Kanno et al




Fig. 1 - Site of banding with a vascular graft. In order to prevent slippage at the banding site, the vascular graft is turned inside out and wrapped around the blood vessel. Both ends of the vascular graft are fixed by two Z-sutures on the proximal and distal sides (arrow). The tightness of the banding is adjusted to the target FV according to blood flow volume measurement by ultrasound.





Fig 2. The enlarged anastomosis and dilated shunt vein before (A) and after T-banding (B).




Fig 3. T-band in situ covering the anastomosis of an upper arm fistula.

Flow reduction - External Wrap

404 Schneider et al

JOURNAL OF VASCULAR SURGERY
February 2006

Table II. Pre- and postoperative fistula flow and outcome

Initial	Flow before T-banding (mL/min)	Flow 1-3 months after T-banding (mL/min)	Percent reduction	Primary success	Complications	Reoperation
A. F.	1.600	900	44	Yes		No
S. T.	2.300	1.100	52	Yes	Hematoma	No
A. G. G.	2.100	600	71	Yes	Thrombosis	Yes
D. G.	3.200	1.400	56	No		Yes
S. T.	1.800	ND	—	Yes		No
G. H.	1.600	700	56	Yes		No
A. S.	2.300	1.000	56	No		Yes
N. T. G.	2.100	1.200	43	No		No
T. Z.	ND	800	—	No		No
U. K.	2.500	ND	—	Yes		No
B. D.	1.300	700	46	Yes		No
S. D.	1.800	900	50	Yes	Thrombosis	Yes
D. O.	1.600	900	44	Yes		No
E. K.	2.300	1.400	39	No		Yes
E. N.	2.100	1.200	43	No		Yes
A. E.	2.200	800	64	Yes		No
R. G.	1.500	1.100	27	Yes	Hematoma	No
H. J. K.	1.300	800	39	Yes		No
T. S.	2.500	1.100	56	Yes		No
K. G.	1.300	ND	—	Yes		No
C. S.	1.800	1.000	44	Yes		No
W. S.	1.600	900	44	Yes		No
N = 18	1956 ± 482	983 ± 228	44			

Primary success, Relief of symptoms.

Mean ± SD for flow measurements, and median for percent flow reduction.




Fig 3. T-band in situ covering the anastomosis of an upper arm fistula.



Success = 16/22 = 72%

(95% for flow reduction)

But FLOW RATES low
1956m/min (1300 to 3200)

Treatment – Flow reduction – interposition graft

288 Hashimoto et al



Flow reduction
52.7% to 67.8%

(3446 +/- 1489 mL/min vs
1502 +/- 527 mL/min;
52.4% decrease

Mean access flow
volume at 2 years = 1623
+/- 320 mL/min

Revision using Distal Inflow (RUDI)




Fig. 4 - RUDI - the fistula is supplied from the more distal vessel below the arterial bifurcation, which restores normal direction blood flow in the partnering forearm artery.

Gerrickens, M.W.M. et al 3- year patency and recurrence rates of revision using distal inflow with a venous interposition graft for high flow brachial artery based arteriovenous fistula
Eur J Vasc Endovasc Surg. 2018; 55:874-881




Figure 1. Mean access flows prior to revision using distal inflow (RUDI) and within 1 week after RUDI for high flow access (HFA, $n = 14$) and high flow access with concurrent haemodialysis access induced distal ischaemia (HAIDI/HFA, $n = 7$). Missing post-operative flows HAIDI/HFA group: failed RUDI, $n = 1$; pre-dialysis patient $n = 1$.

Immediately post-operatively, flows were 2 L/min lower (3120 mL/min 186 vs. 1170 87 mL/min, $p < .001$).





Figure 1. Mean access flows prior to revision using distal inflow (RUDI) and within 1 week after RUDI for high flow access (HFA, $n = 14$) and high flow access with concurrent haemodialysis access induced distal ischaemia (HAIDI/HFA, $n = 7$). Missing post-operative flows HAIDI/HFA group: failed RUDI, $n = 1$; pre-dialysis patient $n = 1$.

Three accesses (14%) occluded in the first post-operative week.



After 3 years, 51% were free of high flow

Post transplant high flow

From the Eastern Vascular Society



Practice patterns in arteriovenous fistula ligation among kidney transplant recipients in the United States Renal Data Systems



Caitlin W. Hicks, MD, MS,^a Sunjae Bae, MD, MPH,^b Marcos E. Pozo, MD,^b Sandra R. DiBrito, MD, PhD,^b Christopher J. Abularrage, MD,^a Dorry L. Segev, MD,^{b,c} Jacqueline Garonzik-Wang, MD, PhD,^b and Thomas Reifsnyder, MD,^a *Baltimore, Md*

- Very variable practice
- No impact on allograft failure
- No impact on all cause mortality
- Reserve for symptomatic Access

848 Hicks et al




Fig 3. Association of arteriovenous access ligation with allograft failure. Three-year allograft failure occurred in $4.9\% \pm 1.3\%$ of kidney transplant recipients who underwent arteriovenous access ligation vs 9.5% of kidney transplant recipients who did not undergo ligation (log-rank, $P = .30$). The shaded bars represent 95% confidence intervals for both curves; the differentiation between the two highlights the significant overlap between ligation and no ligation.



Flow 3.5L/min

Flow 4L/min

6 years post transplant
GFR 55 and stable

Exercise tolerance – 3m
SOB at rest

Left r/c AVF revised 3 months pre-
transplant

Right BC created with a view of
ligating left

Follow up = maintain fistula if
needed for future use.

High flow Access - Summary

- Definitions are inconsistent
 - >1500ml should warrant surveillance and investigation
 - High flow >2000ml/min
 - Consider intervention
 - Interventions – evidence is low
 - Flow reduction by banding/RUDI
 - Wraps, grafts and MILLER
- recurrence an issue
evidence is low